



ASX ANNOUNCEMENT

12th October 2007

Imugene patent protection extended

Key Porcine Adenoviral Delivery Vector patent to be granted in USA

Imugene (ASX: IMU) has received notice of grant for patent protection for its *Porcine Adenoviral Delivery Vector* technology in the US. The *Porcine Adenoviral Delivery Vector* is the base technology behind all Imugene's pig vaccines. This notice of grant follows the successful defense of the patent interference proceedings in the US which was finalised late last year.

In addition Imugene has been granted a 295 day extension in the life of the patent in recognition of time lost during the interference defense process. This extension means the patent will now expire in late 2021 in the US.

Imugene will now have patent protection for the *Porcine Adenoviral Delivery Vector* technology in both Europe and the US, in addition to other major pig producing countries around the world. The granting of this important patent will provide Imugene with protection in the world's highest volume and value pig product markets.

About Imugene

Imugene specialises in commercialising animal health products for production animals including pigs and poultry.

Imugene owns the worldwide rights to the Fowl Adenoviral Vector Delivery System for poultry and the Porcine Adenoviral Vector Delivery System for pigs. Imugene has successfully licensed the first product based on the Fowl Adenoviral Vector Delivery System – the Poultry Productivity Enhancer.

Imugene's poultry and pig portfolio is targeting a worldwide US\$3 billion annual market with four lead vaccine products under development and a strong product pipeline. Consumer demands for disease free and residue free food will bolster Imugene's prospects.

Imugene's products safely prevent disease and reduce or eliminate antibiotics and harmful chemicals in animals. Animal antibiotics and chemicals in the human food chain have been linked to the emergence of dangerous resistant bacteria in people and food residues.

For more information please visit the Imugene Website www.imugene.com

For more information:

Dr Warwick Lamb
Managing Director
+61 2 9870 7330

Mr Graham Dowland
Executive Chairman
+61 8 9440 2660

Mr Rudi Michelson
Monsoon Communications
+61 3 9620 3333

Perth Office

Level 20, Allendale Square
77 St Georges Terrace
Perth WA 6000
Tel: +61 8 9440 2660
Fax: +61 8 9440 2699

ABN: 99 009 179 551

Sydney Office

Registered Office
Level 1, 14 – 20 Delhi Road
North Ryde NSW 2113
Tel: +61 2 9870 7330
Fax: +61 2 9888 9338

www.imugene.com